Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Esketamine for Treatment-Resistant Depression in MDD
NCT03965858Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of esketamine in major depressive disorder (MDD), treatment-resistant depression (TRD), sponsored by Celon Pharma S.A.. Started Feb 2019; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03965858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965858.